NCT03410901 2024-12-11
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Stanford University
Phase 1 Completed
Clinical Trials
8 trialsNCT06646666 2024-11-01
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
Ruijin Hospital
Phase 2 Not yet recruiting
NCT04097067 2024-08-27
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
University Hospital Muenster
Phase NA Recruiting
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT02266147 2020-09-04
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Dynavax Technologies Corporation
Phase 1/2 Terminated
NCT00841945 2017-02-23
Treatment of Aggressive Localized Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated
NCT00210314 2015-03-30
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT00210379 2009-07-22
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed